Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-11
2006-07-11
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S269700
Reexamination Certificate
active
07074811
ABSTRACT:
A substantially non-hydrated and non-hygroscopic or slightly hygroscopic hydrochloride salt of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; a pharmaceutical composition containing such a compound, a process of preparing such a compound and the use of such a compound in medicine.
REFERENCES:
patent: 5002953 (1991-03-01), Hindley
patent: 5708012 (1998-01-01), Olefsky
patent: 5726055 (1998-03-01), Hindley et al.
patent: 5741803 (1998-04-01), Pool et al.
patent: 5910592 (1999-06-01), Pool et al.
patent: 6288095 (2001-09-01), Hindley
patent: 6664278 (2003-12-01), Sasse et al.
patent: 2002/0137940 (2002-09-01), Sasse et al.
patent: 2003/0120078 (2003-06-01), Sasse et al.
patent: 1277965 (2000-12-01), None
patent: 0 306 228 (1989-03-01), None
patent: WO 94/05659 (1994-03-01), None
patent: WO 98/57634 (1998-12-01), None
patent: WO 00/63205 (2000-10-01), None
patent: WO 00/63206 (2000-10-01), None
patent: WO 00/64892 (2000-11-01), None
patent: WO 00/64893 (2000-11-01), None
patent: WO 00/64896 (2000-11-01), None
patent: WO 01/44240 (2001-06-01), None
patent: WO 02/20519 (2002-03-01), None
H.G. Brittain. “Polymorphism in Pharmaceutical Solids”,Drugs and the Pharmaceutical Sciences, 95:126-358 (1999).
Smith et al., “Treatment of Diabetes with Thiazolidinedione and Metformin”. CA 130:61089 (WO 98/57634), 1998.
A.M. Rouhi. “The Right Stuff”.Chemical and Engineering News, Feb. 24, 2003, pp. 32-34.
Cantello et al., “Facile Biocatalytic Reduction . . . Enantiomer and Analogues”,Journal of the Chemical Society, Perkin Transactions 1, pp. 3319-3322 (1994).
Haleblian et al., “Pharmaceutical Applications of Polymorphism”,Journal of Pharmaceutical Sciences, 58(8): 911-929 (1969).
H.G. Brittain. “Polymorphism in Pharmaceutical Solids”, NY: Marcel Dekker, Inc. 1999, pp. 125-181, 183-226, 228-330.
J.R. Durbin, “Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance,”Diabetes, Obesity and Metabolism, 6, 280-285 (2004).
Davis Zinna Northington
Kinzig Charles M.
Sieburth Kathryn L.
SmithKline Beecham p.l.c.
Venetianer Stephen
LandOfFree
Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3606470